Acquisition, Divestitures, Licensing Arrangements, Collaborative Arrangements and Privately Held Investment - Cerevel (Details) - USD ($)		1 Months Ended	3 Months Ended			9 Months Ended
		Sep. 30, 2018	Sep. 30, 2018		Oct. 01, 2017	Sep. 30, 2018		Oct. 01, 2017
Investment [Line Items]
Pre-tax gain associated with the formation of Cerevel	[2]		$ 94,000,000	[1]	$ 45,000,000	$ 460,000,000	[1]	$ 111,000,000
Bain Capital [Member] | Cerevel [Member]
Investment [Line Items]
Pre-tax gain associated with the formation of Cerevel		$ 343,000,000	343,000,000
Transfer of Assets [Member] | Neuroscience Assets [Member] | Bain Capital [Member] | Cerevel [Member]
Investment [Line Items]
Committed investment by Bain Capital		350,000,000	350,000,000			350,000,000
Book value of assets transferred		$ 0	$ 0			$ 0
Cerevel Therapeutics [Member] | Cerevel [Member]
Investment [Line Items]
Investment ownership percentage		25.00%

[1] The net gains on investments in equity securities are reported in Other (income)/deductions––net and, for the third quarter and first nine months of 2018, include unrealized net gains on equity securities reflecting the adoption of a new accounting standard in the first quarter of 2018. For additional information, see Note 4.

[2] The net gains on investments in equity securities for the third quarter of 2018 include unrealized net gains on equity securities of $8 million and, for the first nine months of 2018, include unrealized net gains on equity securities of $344 million, reflecting the adoption of a new accounting standard in the first quarter of 2018. We continue to hold 2.5 million shares of ICU Medical common stock and we recognized unrealized gains of $24 million in the third quarter of 2018 and unrealized gains of $229 million in the first nine months of 2018 related to these remaining shares. Prior to the adoption of a new accounting standard in the first quarter of 2018, net unrealized gains and losses on virtually all equity securities with readily determinable fair values were reported in Accumulated other comprehensive income. For additional information, see Note 1B, Note 2B and Note 7B.